论文部分内容阅读
Lovastatin抑制肝脏合成胆固醇,增加肝脏LDL受体;通过受体介导来清除血浆LDL,有效剂量每日80mg。 8245例中度高胆固醇血症,随机分为五组(每组1642～1663例):Ⅰ组(本品20mg每日1次)、Ⅱ组(40mg每日1次)、Ⅲ组(20mg每日2次)、Ⅳ组(40mg每日2次)和安慰剂组。治疗48周后,Ⅰ组血脂水平与对照组呈现显著差异(P<0.001),不同剂量组间彼此有明显差异(P<0.001)。四个不同剂量组分别使LDL-胆固醇下降24、30、34和40％,有明显的剂量相关性;80～96％患者LDL-胆固醇降至<4.14mmol/L(<160
Lovastatin inhibits the synthesis of cholesterol in the liver and increases hepatic LDL receptors. It clears plasma LDL through receptor-mediated therapy at an effective dose of 80 mg daily. 8245 cases of moderate hypercholesterolemia were randomly divided into five groups (1642 ~ 1663 in each group): group Ⅰ (20mg once daily), group Ⅱ (40mg once daily), group Ⅲ (20mg / Day 2), group IV (40 mg twice daily), and placebo. After 48 weeks of treatment, there was a significant difference (P <0.001) between the level of serum lipid and the control group (P <0.001). LDL-cholesterol decreased by 24, 30, 34 and 40% in four different dose groups, respectively, with a significant dose-related effect; LDL-cholesterol dropped to <4.14 mmol / L in 80 to 96% of patients